Recombinant interferon-alpha 2b and megestrol acetate in patients with advanced renal cell carcinoma
Voravud, N.; Sriuranpong, V.; Lertsaguansinchai, P.
Journal of the Medical Association of Thailand 83(2): 123-128
2000
ISSN/ISBN: 0125-2208 PMID: 10710880 Document Number: 1882
Fifteen patients with histologically proven metastatic or unresectable renal cell carcinoma were enrolled for a phase II trial of Interferon-alpha 2b (> or = 6 x 10(6) U/m2) plus megestrol acetate (160 mg/day). A response rate of 14.3 per cent was achieved in this study. We observed weight gain (median 3.2 kilogram; range 1.1 to 6.9) in 5 patients, and stable weight in 5 of the 14 patients who completed the protocol. Weight gain occurred regardless of extent of metastasis or response to interferon. Our data suggest a possible role for megestrol acetate in alleviating anorexia and weight loss in patients with renal cell carcinoma undergoing interferon treatment. Further clinical trials are clearly warranted.
Document emailed within 1 workday
